Novel therapies focused on the high-density lipoprotein particle.

@article{Capelleveen2014NovelTF,
  title={Novel therapies focused on the high-density lipoprotein particle.},
  author={Julian C. van Capelleveen and Hollis B Brewer and John J. P. Kastelein and G. K. Hovingh},
  journal={Circulation research},
  year={2014},
  volume={114 1},
  pages={193-204}
}
Cardiovascular disease (CVD) remains a major burden for morbidity and mortality in the general population, despite current efficacious low-density lipoprotein-cholesterol-lowering therapies. Consequently, novel therapies are required to reduce this residual risk. Prospective epidemiological studies have shown that high-density lipoprotein-cholesterol (HDL-C) levels are inversely correlated with cardiovascular disease risk, and this initiated the quest for HDL-C-increasing therapies… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 106 references

Presentation: IV single-dose ACP-501 (rhLCAT) is well-tolerated, raises HDL-C in those with low HDL with CAD

  • R. Shamburek
  • ATVB Scientific Sessions. May
  • 2013
Highly Influential
4 Excerpts

Abstract 18667

  • M Goffinet, C Tardy, +6 authors JL. Dasseux
  • American Heart Association Scientific Sessions
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…